Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, has announced the pricing of its upsized underwritten public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is expected to raise approximately $225.5 million in gross proceeds, before deducting underwriting discounts and commissions and other offering expenses.

The company is offering 3,918,182 shares of common stock and pre-funded warrants to purchase 181,818 shares of common stock at an offering price of $55.00 per share and $54.9999 per pre-funded warrant, respectively. The aggregate gross proceeds to Disc from this offering are expected to be approximately $225.5 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional $33.825 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.

The securities described above are being offered by Disc pursuant to an automatic shelf registration statement on Form S-3 (No. 333-281359) that was previously filed with the Securities and Exchange Commission (SEC) on August 8, 2024. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting the underwriters.

Disc intends to use the net proceeds from the offering to fund research and clinical development of its current or additional product candidates, to support the potential commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), as well as for working capital and other general corporate purposes.

Jefferies, Leerink Partners, Stifel, and Cantor are acting as joint book-running managers for the offering. BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, and H.C. Wainwright & Co. are acting as co-managers for the offering.




The successful pricing of this upsized public offering demonstrates the strong investor interest in Disc Medicine's mission and pipeline. The company's focus on discovering, developing, and commercializing novel treatments for serious hematologic diseases has resonated with investors, who are eager to support the company's growth and potential success. The proceeds from this offering will enable Disc Medicine to accelerate its pipeline development, expand its operations, and potentially commercialize its products, including bitopertin for EPP and XLP.

Investors should closely monitor Disc Medicine's progress and consider the potential benefits and risks associated with the company's offerings and pipeline development. As the company continues to grow and advance its pipeline, it may present attractive investment opportunities for those seeking exposure to the biopharmaceutical sector.